Report Company Directory
- Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 by GlobeNewsWire
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) by GlobeNewsWire
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 by GlobeNewsWire
- HOLT Healthcare "Measuring the Pulse of U.S. Healthcare: Looking to 2026..." by UBS AG
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day by GlobeNewsWire
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update by GlobeNewsWire
- Vital Signs: Actionable charts by Vermilion Research
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 by GlobeNewsWire
- Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) by GlobeNewsWire
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List by GlobeNewsWire